Mumbai, Janaury 04, 2018: Biotechnology mAJOR, Biocon and Mylan have received approval for Biosimilar Trastuzumab from ANVISA, the Brazilian regulatory agency, through their partner Libbs Farmaceutica (Libbs), a leading Brazilian pharmaceutical company.
Co-developed by Biocon and Mylan, this is the first biosimilar Trastuzumab to be approved in Brazil and is indicated for the treatment of overexpressing HER2-positive metastatic breast cancer, HER2- positive early stage breast cancer and HER2-positive advanced gastric cancer. Libbs will commercialize the product in Brazil under the brand name Zedora, which will provide affordable access to a cutting-edge biologics therapy for patients in Brazil.
United News of India
· The Telerobotic-assisted Internal Mammary Artery Harvesting procedure was successfully completed in 58 minutes, with exceptional precision and…
This expansion enables DFE Pharma to offer specialized analytical services for Dry Powder Inhalation (DPI)…
Dr. Sujatha Thyagarajan, Lead & HOD - Pediatric Intensive Care and Pediatric Emergency at Aster…
Bangalore, January 13, 2025: Fortis Hospital Bannerghatta Road, has successfully treated a 53-year-old software engineer from…
Mumbai, January 13, 2025: In a landmark medical feat, a multidisciplinary team led by Dr.…
Mumbai, January 13, 2025: From the last six months, 21-year-old Pari Tulaskar [name changed) from…